2006
DOI: 10.1016/j.ymgme.2006.04.010
|View full text |Cite
|
Sign up to set email alerts
|

Two novel CLN5 mutations in a Portuguese patient with vLINCL: Insights into molecular mechanisms of CLN5 deficiency

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

6
38
0

Year Published

2009
2009
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 32 publications
(44 citation statements)
references
References 34 publications
6
38
0
Order By: Relevance
“…In humans, the CLN5 gene maps to chromosome 13q22, consists of 4 exons spanning 13 kb of genomic DNA, and encodes a protein of 407 amino acids. The predicted amino acid sequence of CLN5 shows no homology to previously reported proteins, and although several studies suggested that CLN5 has at least one transmembrane domain (4,33,38), other studies report that it may be a soluble protein (16). Whereas transfection of COS-1 cells with CLN5 cDNA results in the synthesis of a highly glycosylated 60-kDa polypeptide, 47-, 44-, 42-, and 40-kDa polypeptides were produced in cell-free translation assays due to usage of the alternative initiator methionine (17).…”
mentioning
confidence: 63%
“…In humans, the CLN5 gene maps to chromosome 13q22, consists of 4 exons spanning 13 kb of genomic DNA, and encodes a protein of 407 amino acids. The predicted amino acid sequence of CLN5 shows no homology to previously reported proteins, and although several studies suggested that CLN5 has at least one transmembrane domain (4,33,38), other studies report that it may be a soluble protein (16). Whereas transfection of COS-1 cells with CLN5 cDNA results in the synthesis of a highly glycosylated 60-kDa polypeptide, 47-, 44-, 42-, and 40-kDa polypeptides were produced in cell-free translation assays due to usage of the alternative initiator methionine (17).…”
mentioning
confidence: 63%
“…Another consanguineous Asian family, of Afghan origin, was also identified with a mutation in CLN5. During the course of this study other reports have been published describing European, non-Finnish CLN5 patients (Bessa et al, 2006;Cannelli et al, 2007). The patients reported here represent the first cases of NCL disease caused by mutations in CLN5 originating from the Indian subcontinent.…”
Section: Introductionmentioning
confidence: 77%
“…Additionally, we analyzed the recently described, but also uncharacterized disease mutations at amino acid 112, found in a Portuguese family (p.R112P; POR) and a Colombian patient (p.R112H; COL). The Portuguese patient is a compound heterozygous carrying a null mutation (p.Q189X) in one allele and two mutations (p.R112P and p.D279N) in the other allele [Bessa et al, 2006]. The Colombian patient has been described to present a juvenile-onset phenotype [Pineda-Trujillo et al, 2005].…”
Section: S] Methionine (B)mentioning
confidence: 99%
“…Due to eight potential N-glycosylation sites, the CLN5 protein has been shown to have an observed molecular mass of 52-75 kDa with both high mannose-type and complex-type sugars Vesa et al, 2002]. The solubility of the CLN5 protein has been controversially discussed [Bessa et al, 2006;Isosomppi et al, 2002;Savukoski et al, 1998;Vesa et al, 2002]. However, it has been reported that human CLN5 contains mannose 6-phosphate (Man 6-P) residues on high mannose-type oligosaccharides linked to Asn320, Asn330, and Asn401, supporting the existence of soluble CLN5 variants [Sleat et al, 2006].…”
Section: Introductionmentioning
confidence: 99%